glp 1 and parkinson's Incretin insulin signaling as novel therapeutic targets for Alzheimer's and disease GLP-1 Receptor Agonists for Parkinson's

This paradigm shift will open the door to microbiota-specific therapiesincluding psychobiotics or neuro-modulatory prebiotics working at the nexus of gut-brain-skeletonto rectify post-menopausal osteoporosis through improved neuropsychiatric outcomes

Potential improvement in cardiovascular risk factors : Weight loss and better glycemic control may favorably impact blood pressure, lipids, etc

3.2 Direct hepatocyte protection: membrane stabilization and antioxidant effects 3.2.1 Membrane stabilization The amphiphilic structure of glycyrrhizin enables it to intercalate into the phospholipid bilayer of hepatocyte membranes, primarily in the outer layer

Common Mild Side Effects These typically appear during the first few weeks of use: Increased hunger Especially with Ipamorelin due to ghrelin receptor stimulation Mild water retention Often resolves after the body adjusts Tingling or numbness Usually in fingers or hands (transient) Lightheadedness More common with higher doses or low-carb diets Most of these effects are dose-dependent and subside within a week or two